CN116139235B - 一种具有缓解青少年视疲劳作用的药食两用组合物及其制备方法与应用 - Google Patents
一种具有缓解青少年视疲劳作用的药食两用组合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN116139235B CN116139235B CN202111383763.5A CN202111383763A CN116139235B CN 116139235 B CN116139235 B CN 116139235B CN 202111383763 A CN202111383763 A CN 202111383763A CN 116139235 B CN116139235 B CN 116139235B
- Authority
- CN
- China
- Prior art keywords
- parts
- teenagers
- composition
- chrysanthemum
- asthenopia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 80
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 39
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 35
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 30
- 239000000843 powder Substances 0.000 claims abstract description 30
- 230000000694 effects Effects 0.000 claims abstract description 26
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 23
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 23
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 23
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 23
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 22
- 235000012680 lutein Nutrition 0.000 claims abstract description 20
- 239000001656 lutein Substances 0.000 claims abstract description 20
- 229960005375 lutein Drugs 0.000 claims abstract description 20
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 20
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 20
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 20
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims abstract description 19
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 19
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 19
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims abstract description 19
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims abstract description 19
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims abstract description 19
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 19
- 229960003080 taurine Drugs 0.000 claims abstract description 19
- 235000010930 zeaxanthin Nutrition 0.000 claims abstract description 19
- 239000001775 zeaxanthin Substances 0.000 claims abstract description 19
- 229940043269 zeaxanthin Drugs 0.000 claims abstract description 19
- 235000016357 Mirtillo rosso Nutrition 0.000 claims abstract description 18
- 244000077923 Vaccinium vitis idaea Species 0.000 claims abstract description 18
- 235000017606 Vaccinium vitis idaea Nutrition 0.000 claims abstract description 18
- 230000004438 eyesight Effects 0.000 claims abstract description 18
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 16
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 16
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 16
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 16
- 244000197580 Poria cocos Species 0.000 claims abstract description 16
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 16
- 241000196324 Embryophyta Species 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 41
- 238000002156 mixing Methods 0.000 claims description 39
- 239000000341 volatile oil Substances 0.000 claims description 31
- 238000001035 drying Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 13
- 239000000654 additive Substances 0.000 claims description 12
- 230000000996 additive effect Effects 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 12
- 239000011812 mixed powder Substances 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 12
- 238000004821 distillation Methods 0.000 claims description 7
- 229920000858 Cyclodextrin Polymers 0.000 claims description 6
- 239000001116 FEMA 4028 Substances 0.000 claims description 6
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 6
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 6
- 229960004853 betadex Drugs 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 6
- 241000572565 Alpinia oxyphylla Species 0.000 claims description 5
- 241000628997 Flos Species 0.000 claims description 5
- 244000241838 Lycium barbarum Species 0.000 claims description 5
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 5
- 235000015468 Lycium chinense Nutrition 0.000 claims description 5
- 239000006260 foam Substances 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- 238000001256 steam distillation Methods 0.000 claims description 5
- 241000723353 Chrysanthemum Species 0.000 claims 9
- 235000013305 food Nutrition 0.000 abstract description 26
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract description 21
- 230000036541 health Effects 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 40
- 230000006378 damage Effects 0.000 description 23
- 230000003078 antioxidant effect Effects 0.000 description 17
- 239000003963 antioxidant agent Substances 0.000 description 16
- 235000006708 antioxidants Nutrition 0.000 description 14
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 235000009508 confectionery Nutrition 0.000 description 13
- 239000000499 gel Substances 0.000 description 13
- 208000014674 injury Diseases 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 210000000695 crystalline len Anatomy 0.000 description 10
- 210000001525 retina Anatomy 0.000 description 10
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 229940118019 malondialdehyde Drugs 0.000 description 9
- 239000003642 reactive oxygen metabolite Substances 0.000 description 9
- 238000005286 illumination Methods 0.000 description 8
- 230000036542 oxidative stress Effects 0.000 description 8
- 102000016938 Catalase Human genes 0.000 description 7
- 108010053835 Catalase Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 102000019197 Superoxide Dismutase Human genes 0.000 description 7
- 108010012715 Superoxide dismutase Proteins 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 230000004382 visual function Effects 0.000 description 7
- 230000009977 dual effect Effects 0.000 description 6
- 210000001508 eye Anatomy 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000012452 mother liquor Substances 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000004379 myopia Effects 0.000 description 5
- 208000001491 myopia Diseases 0.000 description 5
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 210000005252 bulbus oculi Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 230000004792 oxidative damage Effects 0.000 description 4
- 239000000419 plant extract Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 230000008832 photodamage Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- -1 GSH-Px Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 101001009581 Molluscum contagiosum virus subtype 1 Glutathione peroxidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000006667 mitochondrial pathway Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000013386 optimize process Methods 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/366—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种具有缓解青少年视疲劳作用的药食两用组合物及其制备方法,它由茯苓50~150份,越橘40~100份,枸杞子20~60份,山药10~50份,菊花10~50份,益智仁5~20份,植物乳杆菌干粉3~8份,牛磺酸0.5~2份,叶黄素0.05~0.2份,玉米黄素0.01~0.05份制成。本发明提供的药食两用组合物,通过大量试验筛选制备得到,采用具有多重保健功效的天然传统药食两用植物制备而成,无毒副作用、健康安全,实验结果表明,具有保护青少年视力的作用,可广泛应用于青少年视力健康。
Description
技术领域
本发明涉及一种药食两用组合物,特别是涉及一种具有缓解青少年视疲劳作用的枸杞子组合物及其制备方法与应用。
背景技术
现代社会中,随着科技的发展和生活、工作的需要,人类在智能手机、电脑、电视机上花费的时间越来越多。由这些电子设备所释放出的光污染对人的健康影响,越来越受到世人关注。因此,亟待采取相应措施,进行干预。
现代研究显示,人眼的晶状体承担着成像和保护视网膜的双重作用,有效隔绝了紫外线和红外线。但对于光能量最大的蓝光,可直接穿过晶状体到达视网膜在眼底成像,对视网膜造成不可逆转的伤害,轻则近视,严重的会导致眼部失明。其主要机理为蓝光会导致感光细胞或视网膜色素上皮细胞损伤,该损伤是以光化学损伤为主,进而引起细胞的凋亡甚至死亡。其中线粒体途径引起的氧化应激反应及细胞凋亡在蓝光诱导的视网膜损伤中具有重要作用。
青少年眼睛结构尚处于发育阶段,更易受到上述不良光线的影响,极易损伤视网膜造成视疲劳,进而通过巩膜重塑发展成为近视。目前有关近视的治疗除手术干预外,尚无有效手段。因此,基于中医药及现代营养学理论,开展青少年抵御视网膜蓝光损伤,缓解视疲劳的发生发展,开发相关食疗产品,以延缓近视的发生具有广阔的市场前景。
发明内容
发明目的:本发明的目的在于提供一种保护青少年视力作用强,安全性高,无不良反应的药食两用组合物。本发明的另一目的是提供上述组合物的制备方法和应用。
技术方案:为了实现以上目的,本发明采取的技术方案为:
一种具有缓解青少年视疲劳作用的药食两用组合物,它由下列重量份数的原料制成:茯苓50~150份,越橘40~100份,枸杞子20~60份,山药10~50份,菊花10~50份,益智仁5~20 份,植物乳杆菌干粉3~8份,牛磺酸0.5~2份,叶黄素0.05~0.2份,玉米黄素0.01~0.05份。
作为优选方案,以上所述的具有缓解青少年视疲劳作用的药食两用组合物,它由下列重量份数的原料制成:茯苓60~100份,越橘50~80份,枸杞子30~50份,山药20~30份,菊花30~50份,益智仁8~12份,植物乳杆菌干粉4~6份,牛磺酸0.8~1.5份,叶黄素0.08~0.12 份,玉米黄素0.01~0.03份。
作为更优选方案,所述的具有缓解青少年视疲劳作用的药食两用组合物,它由下列重量份数的原料制成:茯苓80份,越橘60份,枸杞子40份,山药20份,菊花40份,益智仁 10份,植物乳杆菌干粉5份,牛磺酸1份,叶黄素0.1份,玉米黄素0.02份。
本发明所述的具有缓解青少年视疲劳作用的药食两用组合物的制备方法,其包括以下步骤:
(1)按重量份数分别取菊花、益智仁用水蒸汽蒸馏法提取挥发性精油,分离得到菊花益智仁混合精油;再加水煎煮,分离得到菊花益智仁混合水煎液;
(2)按重量份数分别取茯苓、越橘、枸杞子、山药混合加水煎煮,分离得到混合水煎液;
(3)取步骤(1)所得菊花益智仁混合水煎液和步骤(2)所得混合水煎液,混合,真空浓缩得到浓缩液;
(4)取步骤(4)所得浓缩液,用喷雾干燥法或真空泡沫干燥法进行干燥,得到植物提取物粉;
(5)取步骤(1)所得的菊花益智仁混合精油,用β-环糊精包合,制成粉状精油包合物;
(6)按权利要求1至3所述的重量份数分别取植物乳杆菌干粉、牛磺酸、叶黄素、玉米黄素,混合均匀得组分添加物混合粉;
(7)取步骤(5)所得精油包合物、步骤(6)所得组分添加物混合粉,加入步骤(4) 所得枸杞子等植物混合提取物粉,混合均匀,即得具有缓解青少年视疲劳作用的药食两用组合物。
作为优选方案,以上所述的具有缓解青少年视疲劳作用的药食两用组合物的制备方法,步骤(1)水蒸汽蒸馏的条件为:饱和蒸汽压力0.2-0.4Kg/cm2,蒸馏温度100℃,蒸馏时间3-5h;水煎提取温度95-100℃,提取次数2次,提取时间每次1小时;水煎提取温度95-100℃,提取次数2次,提取时间每次1小时。
作为优选方案,以上所述的具有缓解青少年视疲劳作用的药食两用组合物的制备方法,步骤(2)水煎提取温度95-100℃,提取次数2次,提取时间每次1小时。
作为优选方案,以上所述的具有缓解青少年视疲劳作用的药食两用组合物的制备方法,步骤(3)真空浓缩的条件为:真空度≤50Pa,浓缩温度≤50℃。
作为优选方案,以上所述的具有缓解青少年视疲劳作用的药食两用组合物的制备方法,步骤(4)喷雾干燥的条件为:干燥温度≤60℃;真空泡沫干燥的条件为:真空度≤30Pa,干燥温度≤50℃。
本发明根据茯苓、越橘、枸杞子、山药、菊花、益智仁中活性植物成分的理化性质及植物乳杆菌干粉、牛磺酸、叶黄素、玉米黄素的理化性质,通过大量实验筛选提取工艺和制备工艺,其中菊花、益智仁采用水蒸汽蒸馏法提取挥发油,具有提取方法自然、提取效率高、对挥发性成分影响小的优点,并因此保障了植物中药辛散药性在调节和保护人体视力、帮助植物色素等保护视力成分向眼部集聚渗透的独特功能。枸杞子等水煎提取工艺均采用最优化工艺参数,具有提取效率高,不会破坏植物中活性成分,杂质成分溶出率低等优点。浓缩干燥采用真空低温工艺可保证其活性成分不被破坏。
经过大量实验研究表明,本发明提供的药食两用组合物不仅能预防大鼠蓝光照射导致的视力下降,提升晶状体抗氧化水平,同时增加动物整体抗氧化能力,表明本发明提供的药食两用组合物可有效因光损伤导致的视疲劳,进而延缓青少年近视的发生发展的保健功能,可应用于制备具有缓解青少年视疲劳的保健食品或药物。
本发明所述的具有缓解青少年视疲劳作用的药食两用组合物在保护青少年视力的应用,将药食两用组合物和食物上可接受的载体制成固体颗粒饮料、压片糖果、凝胶糖果、浓缩膏剂等类型的食物。
本发明提供的具有缓解青少年视疲劳作用的药食两用组合物制成固体颗粒饮料时,把药食两用组合物与稀释剂混合均匀后,使用湿法制粒机或干法制粒机制成固体颗粒饮料。
本发明提供的具有缓解青少年视疲劳作用的药食两用组合物制成压片糖果时,把药食两用组合物和乳糖或可溶性淀粉混合均匀,制成颗粒,然后用压片机压制成压片糖果。
本发明提供的具有缓解青少年视疲劳作用的药食两用组合物制成凝胶糖果时,把药食两用组合物和琼脂、变性淀粉、明胶、果胶、卡拉胶、树胶等凝胶剂混合均匀,用凝胶糖果浇注机制成凝胶糖果。
本发明提供的具有缓解青少年视疲劳作用的药食两用组合物制成浓缩膏剂时,把药食两用组合物提取物浓缩至合适的浓度,与菊花精油、益智仁精油及叶黄素等天然植物成分混合调配均匀,用膏体灌装机制成浓缩膏剂。
本发明提供的药食两用组合物制成其它食物剂型时,可按食物常规方法制备得到。
有益效果:
本发明是基于中医药理论与青少年视疲劳及蓝光损伤视功能的病理机制,优选得到的预防青少年视疲劳及抵御视网膜蓝光损伤的有效组合物。
中医学认为,眼之所以能明视万物,辨别颜色,是赖五脏六腑精气血的濡养,其与肝、肾、脾的关系尤为密切。因此,只有脏腑功能正常,才能保证精、气、血充盈,抵御外界伤害,从根本上解决视物障碍、视功能损伤问题。本发明提供的药食两用组合物中,茯苓健脾利湿,通调水道,即可助脾健运化生水谷精微,又免湿聚眼底之患。山药健脾补肺、固肾益精,枸杞子滋肝补肾、益精明目,益智仁温脾止泻摄涎,暖肾缩尿固精。四药合用肝、肾、脾同补,辅用菊花平肝明目,避免肝阳上亢,气血畅达眼底。诸药共用,使目中精血充足,目视精明。从组合物中药物的化学组成及现代药理研究来看,越橘中含有花青素类组分具有较强的抗氧化作用,可防止视网膜氧化损伤;茯苓和枸杞子中的多糖类组分可通过调节肠道菌群结构,辅以植物乳杆菌,从肠道免疫调节角度干预视功能损伤;枸杞子中含有的类胡萝卜素成分,以及添加的叶黄素、玉米黄素作为视黄醛的前体物质,一方面可有效保护视网膜色素上皮细胞氧化与炎性损伤,防止黄斑色素减退;另一方面可通过滤过可见光中引起光损伤的短波长光保护视网膜免受损伤,保护视网膜神经节细胞免受缺氧和氧化损伤。牛磺酸可抗脂质过氧化、提高抗氧化酶活性、抑制细胞凋亡等途径,保护视网膜抵御光损伤,发挥保护作用。
本发明通过大量实验筛选各组分的配比,科学合理;并且整个制备工艺,自动化程度高,制备效率高,能很好地保留原料中的有效成分。尤其重要的是,该药食两用组合物所有组成药味与成分均为药食两用品种,安全性好,适合长期使用,可以起到改善视疲劳、抵御视网膜蓝光损伤的效果。
具体实施方式
下面结合具体实施例进一步阐明本发明,应理解这些实施例仅用于说明本发明而不用于限制本发明的范围,在阅读了本发明之后,本领域技术人员对本发明的各种等价形式的修改均落于本申请所附权利要求所限定的范围。
实施例1
1、一种具有缓解青少年视疲劳作用的药食两用组合物,其由下列重量份数的原料制成:菊花40份、益智仁10份、茯苓80份、越橘60份、枸杞子40份、山药20份、植物乳杆菌干粉5份、牛磺酸1份、叶黄素0.1份、玉米黄素0.02份。
2、一种具有缓解青少年视疲劳作用的药食两用组合物的制备方法,包括如下步骤:
(1)取菊花40份、益智仁10份,用水蒸汽蒸馏法在饱和蒸汽压力0.3Kg/cm2,100℃蒸馏4小时,提取挥发性精油,分别收集菊花益智仁精油和蒸馏母液备用;药渣再加入药材重量8倍量的水回流提取1小时,过滤,收集滤液与蒸馏母液合并备用;
(2)取茯苓80份、越橘60份、枸杞子40份、山药20份,加入药材重量8倍量的水回流提取2次,每次1小时,过滤,收集、合并二次滤液,得到混合水煎液备用;
(3)取步骤(1)所得合并液与步骤(2)所得混合水煎液合并,在真空度≤50Pa、浓缩温度≤50℃条件下浓缩得到浓缩液;
(4)取步骤(3)所得浓缩液,在干燥温度≤60℃条件下喷雾干燥,得到枸杞子等植物混合提取物粉;
(5)取步骤(1)所得菊花益智仁精油,用β-环糊精包合,加入重量比10倍量β-环糊精及加4倍量水,研磨1h,干燥,制成粉状精油包合物;
,制成粉状精油包合物;
(6)取植物乳杆菌干粉5份、牛磺酸1份、叶黄素0.1份、玉米黄素0.02份,混合均匀得组分添加物混合粉;
(7)取步骤(5)所得精油包合物、步骤(6)所得组分添加物混合粉,加入步骤(4) 所得枸杞子等植物混合提取物粉,混合均匀,即得药食两用组合物。
实施例2
1、一种具有缓解青少年视疲劳作用的药食两用组合物,其由下列重量份数的原料制成:
菊花50份、益智仁12份、茯苓60份、越橘50份、枸杞子45份、山药25份、植物乳杆菌干粉4份、牛磺酸1.2份、叶黄素0.12份、玉米黄素0.03份。
2、一种具有缓解青少年视疲劳作用的药食两用组合物及其制备方法,包括如下步骤:
(1)取菊花50份、益智仁12份,用水蒸汽蒸馏法在饱和蒸汽压力0.25Kg/cm2,100℃蒸馏3小时,提取挥发性精油,分别收集菊花益智仁精油和蒸馏母液备用;药渣再加入药材重量8倍量的水回流提取1小时,过滤,收集滤液与蒸馏母液合并备用;
(2)取茯苓60份、越橘50份、枸杞子45份、山药25份,加入药材重量8倍量的水回流提取2次,每次1小时,过滤,收集、合并二次滤液,得到混合水煎液备用;
(3)取步骤(1)所得合并液与步骤(2)所得混合水煎液合并,在真空度≤50Pa、浓缩温度≤50℃条件下浓缩得到浓缩液;
(4)取步骤(3)所得浓缩液,在真空度≤30Pa、干燥温度≤50℃条件下真空泡沫干燥,得到枸杞子等植物混合提取物粉;
(5)取步骤(1)所得菊花益智仁精油,加入重量比10倍量β-环糊精及加4倍量水,研磨1h,干燥,制成粉状精油包合物;
(6)取植物乳杆菌干粉4份、牛磺酸1.2份、叶黄素0.12份、玉米黄素0.03份,混合均匀得组分添加物混合粉;
(7)取步骤(5)所得精油包合物、步骤(6)所得组分添加物混合粉,加入步骤(4) 所得枸杞子等植物混合提取物粉,混合均匀,即得药食两用组合物。
实施例3
1、一种具有缓解青少年视疲劳作用的药食两用组合物,其由下列重量份数的原料制成:
菊花10份、益智仁20份、茯苓120份、越橘40份、枸杞子60份、山药10份、植物乳杆菌干粉3份、牛磺酸0.5份、叶黄素0.2份、玉米黄素0.05份。
2、一种具有缓解青少年视疲劳作用的药食两用组合物及其制备方法,包括如下步骤:
(1)取菊花10份、益智仁20份,用水蒸汽蒸馏法在饱和蒸汽压力0.3Kg/cm2,100℃蒸馏3小时,提取挥发性精油,分别收集菊花益智仁精油和蒸馏母液备用;药渣再加入药材重量8倍量的水回流提取1小时,过滤,收集滤液与蒸馏母液合并备用;
(2)取茯苓120份、越橘40份、枸杞子60份、山药10份,加入药材重量8倍量的水回流提取2次,每次1小时,过滤,收集、合并二次滤液,得到混合水煎液备用;
(3)取步骤(1)所得合并液与步骤(2)所得混合水煎液合并,在真空度≤50Pa、浓缩温度≤50℃条件下浓缩得到浓缩液;
(4)取步骤(3)所得浓缩液,在干燥温度≤60℃条件下喷雾干燥,得到枸杞子等植物混合提取物粉;
(5)取步骤(1)所得菊花益智仁精油,加入重量比10倍量β-环糊精及加4倍量水,研磨1h,干燥,制成粉状精油包合物;
(6)取植物乳杆菌干粉3份、牛磺酸0.5份、叶黄素0.2份、玉米黄素0.05份,混合均匀得组分添加物混合粉;
(7)取步骤(5)所得精油包合物、步骤(6)所得组分添加物混合粉,加入步骤(4) 所得枸杞子等植物混合提取物粉,混合均匀,即得药食两用组合物。
实施例4
一种具有缓解青少年视疲劳作用的药食两用组合物固体颗粒饮料的制备方法,包括如下步骤:
(1)取实施例1中步骤(6)所得组分添加物混合粉与步骤(4)所得枸杞子等植物混合提取物粉混合均匀,再加入可溶性淀粉混合均匀,用干法制粒机制成颗粒;
(2)取步骤(1)所得颗粒置混合机中,转动下加入实施例1步骤(5)所得精油包合物,间歇式混合30分钟,混合均匀,用颗粒包装机分装于铝塑复合袋中,每袋10g;
实施例5一种具有缓解青少年视疲劳作用的药食两用组合物压片糖果的制备方法,包括如下步骤:
(1)取实施例2步骤(6)所得组分添加物混合粉与实施例2步骤(4)所得枸杞子等植物混合提取物粉混合均匀,再加入乳糖、可压性淀粉、食用香精香料适量混合均匀;用湿法制粒机制成颗粒,在60℃以下烘干,整粒;
(2)取步骤(1)所得颗粒,加入实施例2步骤(5)所得粉状精油包合物,混合均匀,用压片机压制成压片糖果。
实施例6一种具有缓解青少年视疲劳作用的药食两用组合物凝胶糖果的制备方法,包括如下步骤:
(1)不锈钢调配罐中加入纯化水,搅拌下依次加入琼脂、果胶、可溶性淀粉使完全溶解;搅拌下加入实施例1步骤(7)所得组合物,使完全分散混合均匀,得调配凝胶液;
(2)取步骤(1)所得调配凝胶液,用凝胶糖果浇注机浇注于凝胶糖果模具中,制成凝胶糖果。
实施例7一种具有缓解青少年视疲劳作用的药食两用组合物浓缩膏剂的制备方法,包括如下步骤:
(1)取实施例1步骤(7)所得组合物,加适量水溶解后,加入蜂蜜,加热,混合均匀,得调配浓缩膏;使完全分散混合均匀,得调配凝胶液;
(2)取步骤(1)所得调配浓缩膏液,用膏体灌装机灌装于玻璃瓶中,每瓶250g,或500g;灌装于铝塑条袋中,每袋10g或20g。
实施例8保护视力实验研究
一、实验材料与药物
1.实验动物
SPF级雄性SD大鼠(体重200±20g)购自上海市杰思捷实验动物有限公司(许可证号:SCXK沪2018-0004)。常规饲养于温度保持在(22±2)℃、相对湿度为(60±2)%、光照周期为12h的环境中。
2.药物和试剂
超氧化物歧化酶(SOD)试剂盒、丙二醛(MDA)试剂盒(货号:A003-1)、过氧化氢酶(CAT)试剂盒、谷胱甘肽过氧化物酶(GSH-PX)试剂盒、活性氧(ROS)测试盒、总抗氧化能力(total antioxidant capacity,TAOC)试剂盒均购自南京建成生物工程研究所。
3.实验仪器
光照材料:飞利浦卤素灯,蓝色干涉滤光片(波长450nrn,透过率34%,半宽度9nm,上海海光光学元件厂),光照度计(上海光电研究所),电子温度计,医用铝箔纸。
光照箱:自制光照箱,采用立方形密闭木箱,大小为1×1×1m3,内表面铺设光滑漫反射材料铝箔纸,箱的两侧设置有出气孔。箱内温度设置为22~23℃,并用电子温度计监测。光照箱的侧面分别设置一个直径为2cm的小孔,用卤素灯透过波长为450nm的干涉滤光片,光线均透过侧面小孔进入光照箱,光照度计监测同一水平面的光照强度相同。
二、实验方法
1.大鼠蓝光损伤致视疲劳模型的建立与药食两用组合物给药
健康大鼠适应性喂养5d后,随机分组:正常对照组(无蓝光照射)、模型对照组(蓝光照射)、实施例1给药组(蓝光照射+实施例1药物)、实施例2给药组(蓝光照射+实施例2药物)、实施例3给药组(蓝光照射+实施例3药物)。干预药物分别为每组8只动物,灌胃给药。正常对照组:正常饮食,正常饮水。
模型对照组及各实施例给药组大鼠实验前暗适应36小时,逐只放入光照箱中,接受蓝光连续照射60min后取出。对照组置于室内光线下。模型对照组蓝光照射,喂养3个月。给药组给予蓝光照射的分别按8g/kg剂量灌胃给药。每周记录一次大鼠体重,每天早晚观察大鼠状态,及摄食和饮水情况。
2.大鼠视力评价
给药结束后,将大鼠放置在白箱的中央给予2700lux光照300s,拍摄记录大鼠在白箱中的行为,统计大鼠停留在白箱中的时间。
3.大鼠晶状体中相关抗氧化能力的检测
观察期满,处死动物,摘取眼球,在高倍显微镜下,将晶状体从眼球中剥离出来,剥离过程在冰盘上进行。加入匀浆介质用匀浆器匀浆,4℃环境离心10min(12000r/min),收取上清液,供待检测指标(GSHPx、T-AOC)使用。各项步骤按试剂盒操作说明书上步骤进行。
3.大鼠血清中SOD、GSH-Px、CAT活性和ROS、MDA含量测定
摘取眼球同时眼周围静脉取血,3000rpm、4℃离心10min,分离血清,-20℃保存备用。分别按照SOD、GSH-Px、CAT、ROS、MDA试剂盒说明书测定血清中SOD、GSH-Px、CAT 活性和ROS、MDA含量。
4.统计学处理
所有实验数据均采用SPSS18.0统计处理软件进行统计学处理,结果以表示,组间差异采用t检验,P<0.05为差异有统计学意义。
三、实验结果
1.药食两用组合物对蓝光照射大鼠视力的影响
结果如表1所示,蓝光照射的模型组大鼠在白箱中的停留时间显著长于正常组(P<0.01),说明蓝光照射导致模型组大鼠视力受损。与模型组比较,实施例1、实施例2、实施例3给药组的大鼠,在白箱中的停留时间显著缩短,表明3个实施例的药食两用组合物均对蓝光照射导致的视力损伤具有较好的保护作用,且以最优方案实施例1效果最好。
表1受试样品对模型大鼠视力的影响
动物分组 | 白箱停留时间(与正常组比值,%) |
空白对照组 | 100 |
模型组 | 202±28## |
实施例1给药组 | 142±22** |
实施例2给药组 | 157±31* |
实施例3给药组 | 167±24* |
注:与空白对照组比较,##P<0.01;与模型组比较,*P<0.05,**P<0.01
2.药食两用组合物对蓝光照射大鼠晶状体中相关抗氧化能力的检测
分析大鼠在蓝光照射下,不同实施例组合物对大鼠晶状体内抗氧化能力的影响,结果如表2所示。从GSH-Px和T-AOC两个抗氧化指标上看,模型组大鼠抗氧化值均显著低于空白对照组(P<0.01),各实施例给药组均可不同程度升模型组大鼠抗氧化值(P<0.05),提示各实施例组合物均对光损伤小鼠晶状体具有不同程度的抗氧化能力,且以实施例1组合物表现的抗氧化效果最好。
表2受试样品对模型大鼠晶状体抗氧化指标的影响
注:与空白对照组比较,##P<0.01;与模型组比较,*P<0.05,**P<0.01
3.药食两用组合物对蓝光照射大鼠血清中氧化应激水平的影响
如表3所示,模型对照组大鼠血清中总活性氧(ROS)及脂质过氧化物丙二醛(MDA)水平均显著高于正常对照组(P<0.01),表明蓝光照射的大鼠模型体内存在高水平的氧化应激。
经实施例1、实施例2、实施例3三种不同配比的药食两用组合物灌胃治疗后,与模型对照组比较各实施例组大鼠血清中总ROS水平和MDA含量均显著降低(P<0.05),说明本发明提供的药食两用组合物可改善模型大鼠视网膜的氧化应激状态,减少活性氧及各种氧自由基对大鼠视网膜的损伤,且以实施例1的最优配比降低氧化应激水平最好。
表3受试样品对模型大鼠血清中氧化应激指标的影响
动物分组 | ROS(与正常组比值,%) | MDA(与正常组比值,%) |
空白对照组 | 100 | 100 |
模型组 | 192±21## | 185±12## |
实施例1给药组 | 141±16** | 144±17** |
实施例2给药组 | 152±14* | 157±15* |
实施例3给药组 | 159±18* | 160±14* |
注:与空白对照组比较,##P<0.01;与模型组比较,*P<0.05,**P<0.01
4.药食两用组合物对蓝光照射大鼠血清中体内抗氧化应激酶水平的影响
如表4所示,蓝光照射的模型大鼠与正常对照组比较,血清中SOD、GSH-PX活性显著降低(P<0.01),提示模型大鼠体内由于存在较高水平的氧化损伤,导致抗氧化应激因子水平下降。同时模型组大鼠血清中CAT活性显著下降(P<0.01),提示模型大鼠体内存在氧化应激状态,可对大鼠视网膜组织造成较强氧化损伤。
与模型对照组比较,实施例1、实施例2、实施例3药食两用组合物均可显著提高蓝光照射大鼠血清中SOD、GSH-Px、CAT的活性(P<0.05),其中以实施例1最优配比的效果最显著 (P<0.01),提示本发明提供的药食两用组合物可以提高蓝光照射大鼠血清中抗氧化酶的活性,发挥抗氧化作用,从而改善视网膜的氧化应激状态,抵御视功能蓝光照射损伤
表4受试样品对模型大鼠大鼠血清中体内抗氧化应激酶活性的影响
注:与空白对照组比较,##P<0.01;与模型组比较,*P<0.05,**P<0.01
以上实验结果表明,本发明提供的药食两用组合物具有显著的对抗蓝光照射所致的视功能损伤作用。该组合物不仅能预防大鼠蓝光照射导致的视力下降,提升晶状体抗氧化水平,同时增加动物整体抗氧化能力,表明其可有效降低高氧化应激水平这一导致视功能蓝光损伤的最主要病理环节,从而保护动物视功能免受损伤。尤其重要的是,该药食两用组合物所有组成药味与成分均为药食两用品种,安全性好,适合长期使用,可以起到抵御蓝光照射损伤,缓解视疲劳,保护视力的效果
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (8)
1.一种具有缓解青少年视疲劳作用的组合物,其特征在于,它由下列重量份数的原料制成:茯苓50~150份,越橘40~100份,枸杞子20~60份,山药10~50份,菊花10~50份,益智仁5~20份,植物乳杆菌干粉3~8份,牛磺酸0.5~2份,叶黄素0.05~0.2份,玉米黄素0.01~0.05份。
2.根据权利要求1所述的具有缓解青少年视疲劳作用的组合物,其特征在于,它由下列重量份数的原料制成:茯苓60~100份,越橘50~80份,枸杞子30~50份,山药20~30份,菊花30~50份,益智仁8~12份,植物乳杆菌干粉4~6份,牛磺酸0.8~1.5份,叶黄素0.08~0.12份,玉米黄素0.01~0.03份。
3.根据权利要求2所述的具有缓解青少年视疲劳作用的组合物,其特征在于,它由下列重量份数的原料制成:茯苓80份,越橘60份,枸杞子40份,山药20份,菊花40份,益智仁10份,植物乳杆菌干粉5份,牛磺酸1份,叶黄素0.1份,玉米黄素0.02份。
4.根据权利要求1所述的具有缓解青少年视疲劳作用的组合物,其特征在于,它由下列重量份数的原料制成:菊花10份、益智仁20份、茯苓120份、越橘40份、枸杞子60份、山药10份、植物乳杆菌干粉3份、牛磺酸0.5份、叶黄素0.2份、玉米黄素0.05份。
5.根据权利要求1所述的具有缓解青少年视疲劳作用的组合物,其特征在于,它由下列重量份数的原料制成:菊花50份、益智仁12份、茯苓60份、越橘50份、枸杞子45份、山药25份、植物乳杆菌干粉4份、牛磺酸1.2份、叶黄素0.12份、玉米黄素0.03份。
6.权利要求1~5任一项所述的具有缓解青少年视疲劳作用的组合物的制备方法,其特征在于,包括以下步骤:
(1)按权利要求1至5任一项所述的重量份数分别取菊花、益智仁用水蒸汽蒸馏法提取挥发性精油,分离得到菊花和益智仁混合精油;再加水煎煮,分离得到菊花益智仁混合水煎液;
(2)按权利要求1至5任一项所述的重量份数分别取茯苓、越橘、枸杞子、山药混合加水煎煮,分离得到混合水煎液;
(3)取步骤(1)所得菊花益智仁混合水煎液和步骤(2)所得混合水煎液,混合,真空浓缩得到浓缩液;
(4)取步骤(3)所得浓缩液,用喷雾干燥法或真空泡沫干燥法进行干燥,得到植物混合提取物粉;
(5)取步骤(1)所得的菊花益智仁混合精油,用β-环糊精包合,得混合精油包合物;
(6)按权利要求1至5任一项所述的重量份数分别取植物乳杆菌干粉、牛磺酸、叶黄素、玉米黄素,混合均匀得组分添加物混合粉;
(7)取步骤(5)所得精油包合物、步骤(6)所得组分添加物混合粉,加入步骤(4)所得植物混合提取物粉,混合均匀,即得具有缓解青少年视疲劳作用的组合物。
7.根据权利要求6所述具有缓解青少年视疲劳作用的组合物的制备方法,其特征在于,步骤(1)水蒸汽蒸馏的条件为:饱和蒸汽压力0.2-0.4Kg/cm2,蒸馏温度100℃,蒸馏时间3-5h;水煎提取温度95-100℃,提取次数2次,提取时间每次1小时;
步骤(2)水煎提取温度95-100℃,提取次数2次,提取时间每次1小时;
步骤(3)真空浓缩的条件为:真空度≤50Pa,浓缩温度≤50℃;
步骤(4)喷雾干燥的条件为:干燥温度≤60℃;真空泡沫干燥的条件为:真空度≤30Pa,干燥温度≤50℃。
8.权利要求1至5任一项所述的具有缓解青少年视疲劳作用的组合物在制备保护青少年视力的药品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111383763.5A CN116139235B (zh) | 2021-11-19 | 2021-11-19 | 一种具有缓解青少年视疲劳作用的药食两用组合物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111383763.5A CN116139235B (zh) | 2021-11-19 | 2021-11-19 | 一种具有缓解青少年视疲劳作用的药食两用组合物及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116139235A CN116139235A (zh) | 2023-05-23 |
CN116139235B true CN116139235B (zh) | 2023-11-21 |
Family
ID=86339420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111383763.5A Active CN116139235B (zh) | 2021-11-19 | 2021-11-19 | 一种具有缓解青少年视疲劳作用的药食两用组合物及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116139235B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117771322A (zh) * | 2024-02-26 | 2024-03-29 | 云南红青夫生物科技股份有限公司 | 一种缓解视疲劳的虾青素胶囊 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101248878A (zh) * | 2008-03-28 | 2008-08-27 | 孙景波 | 营养视神经的保健食品及其制备方法 |
CN105535257A (zh) * | 2015-12-24 | 2016-05-04 | 同溢堂药业有限公司 | 一种缓解视疲劳的药物组合物及其制备方法 |
CN111658740A (zh) * | 2020-06-19 | 2020-09-15 | 南京中医药大学 | 具有改善年龄相关性黄斑变性的药食两用组合物及其制备方法与应用 |
CN111686208A (zh) * | 2020-06-20 | 2020-09-22 | 南京中医药大学 | 具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 |
CN113180236A (zh) * | 2021-04-30 | 2021-07-30 | 宁夏枸杞创新中心(有限公司) | 一种法制枸杞子及其制备方法 |
CN113273690A (zh) * | 2021-06-08 | 2021-08-20 | 烟台阿波罗生物药业科技有限公司 | 一种用于改善视疲劳的新资源食品 |
-
2021
- 2021-11-19 CN CN202111383763.5A patent/CN116139235B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101248878A (zh) * | 2008-03-28 | 2008-08-27 | 孙景波 | 营养视神经的保健食品及其制备方法 |
CN105535257A (zh) * | 2015-12-24 | 2016-05-04 | 同溢堂药业有限公司 | 一种缓解视疲劳的药物组合物及其制备方法 |
CN111658740A (zh) * | 2020-06-19 | 2020-09-15 | 南京中医药大学 | 具有改善年龄相关性黄斑变性的药食两用组合物及其制备方法与应用 |
CN111686208A (zh) * | 2020-06-20 | 2020-09-22 | 南京中医药大学 | 具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 |
CN113180236A (zh) * | 2021-04-30 | 2021-07-30 | 宁夏枸杞创新中心(有限公司) | 一种法制枸杞子及其制备方法 |
CN113273690A (zh) * | 2021-06-08 | 2021-08-20 | 烟台阿波罗生物药业科技有限公司 | 一种用于改善视疲劳的新资源食品 |
Non-Patent Citations (3)
Title |
---|
叶黄素对缓解视疲劳人体试食功能试验的研究;刘霁;等;中国药事;第26卷(第08期);第902-905页 * |
近视明口服液的制备及临床应用;张秋月;等;河南中医学院学报;第21卷(第126期);第75-76页 * |
近视明胶囊的制备及临床应用;于红权;;中国医药导报;第07卷(第23期);第105-106页 * |
Also Published As
Publication number | Publication date |
---|---|
CN116139235A (zh) | 2023-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106962909A (zh) | 一种枸杞蜂王浆复合胶囊及其制备方法 | |
CN110292090A (zh) | 一种蓝莓叶黄素酯压片糖果及其制备方法 | |
US20200147166A1 (en) | Health supplement food for promotion of hair growth, mitigation and alleviation of hair loss, regulation of blood glucose, and alleviation and relief of gastric disorder symptoms | |
CN116139235B (zh) | 一种具有缓解青少年视疲劳作用的药食两用组合物及其制备方法与应用 | |
CN105192696A (zh) | 一种保护眼底、营养视网膜及抵御蓝光损伤的组合物及其制备方法 | |
CN1278737C (zh) | 一种具有生物活性的复方药物制剂 | |
CN106109737A (zh) | 一种抗氧化的营养制剂及其制备方法 | |
CN110934976A (zh) | 一种治疗近视的药物及其制备方法 | |
CN110506879A (zh) | 一种缓解视疲劳的固体饮料及其配制方法 | |
EP3881685A1 (en) | Ceratonia siliqua fruit composition and preparation method therefor and use thereof | |
CN108968069A (zh) | 缓解视力疲劳、改善视力、抗氧化、保护视网膜的复合软胶囊及制备方法 | |
KR20080095555A (ko) | 구기자 발효 유지 조성물 | |
CN112618608A (zh) | 具有解酒功能的组合物及其制备方法和应用 | |
CN108066384A (zh) | 一种具有增强免疫力功能的中药制剂及其制备方法 | |
CN106417817A (zh) | 一种袋泡助眠安神茶及其制备方法 | |
CN103609990B (zh) | 脱水蔬菜万年青含片及其制备方法 | |
CN109619189A (zh) | 一种沙棘黑果花楸护眼奶片及其制备方法 | |
CN115444134A (zh) | 一种蓝莓叶黄素酯咀嚼片及制备方法 | |
CN107927091A (zh) | 一种水果蜂蜜蛋糕及其制作方法 | |
CN104673572B (zh) | 具有美容养颜功效的抗衰老葡萄酒及制备方法 | |
CN114432384A (zh) | 一种低氘水龙脑雾化护眼液 | |
KR101241455B1 (ko) | 혈당 강하용 두부 및 그 제조방법 | |
CN106993681A (zh) | 一种保健茯茶 | |
KR101897591B1 (ko) | 고형소재를 함유하는 항산화기능성 베리음료 및 그 제조방법 | |
CN117298142B (zh) | 一种抗视疲劳的组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |